alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › double-blind-placebo-controlled

double-blind-placebo-controlled

8 studies tagged double-blind-placebo-controlled, dated 2006-02-01 to 2023-06-29. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study 2023-06-29
  2. Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial 2021-10-07
  3. Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial 2020-02-06

Studies

8 studies carry this tag.

Date range

2006 to 2023

Top journals

  • BMC complementary medicine and therapies 1
  • BMJ open 1
  • EBioMedicine 1
  • Journal of neurology, neurosurgery, and psychiatry 1
  • Lancet (London, England) 1

8 journals in all.

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. EBioMedicine 2023-06-29 Treatments

    Between 7 December 2015 and 28 August 2018, 43 participants were randomised.

  2. Efficacy and safety of Kami-guibi-tang for mild cognitive impairment: a pilot, randomized, double-blind, placebo-controlled trial

    ✓ Peer-reviewed alzhub usefulness score 79 out of 100. BMC complementary medicine and therapies 2021-10-07 Biomarkers

    KGT may provide a safe and effective treatment option for patients with aMCI.

  3. Antiviral therapy: Valacyclovir Treatment of Alzheimer's Disease (VALAD) Trial: protocol for a randomised, double-blind,placebo-controlled, treatment trial

    ✓ Peer-reviewed alzhub usefulness score 60 out of 100. BMJ open 2020-02-06 Brain scans and imaging

    After infection, herpes simplex virus-1 (HSV1) becomes latent in the trigeminal ganglion and can enter the brain via retrograde axonal transport.

  4. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Journal of neurology, neurosurgery, and psychiatry 2013-11-11 Treatments

    Rivastigmine may represent a new therapeutic option for moderate to severe apathy in advanced PD patients with optimised dopaminergic treatment and without depression dementia.

  5. Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial

    ✓ Peer-reviewed alzhub usefulness score 77 out of 100. The Lancet. Neurology 2013-01-02 Treatments

    Of 100 patients screened, 81 were randomly assigned to receive memantine (39 patients) or placebo (42 patients).

  6. Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial

    ✓ Peer-reviewed alzhub usefulness score 77 out of 100. Lancet (London, England) 2012-01-10 Treatments

    After adjustment for baseline score, there were non-significant differences between groups of -4·1 (95% CI -13·1 to 4·8) in DAMES scores, -8·5 (-20·1 to 3·1) in ABS I scores, and 2·0 (-7·2 to 11·3) in ABS II scores, all in favour of controls. 10 (11%) of 88 participants in the memantine group and six (7%) of 85 controls had serious adverse events (p=0·33).

  7. IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease

    ✓ Peer-reviewed alzhub usefulness score 82 out of 100. Neurology 2007-07-01 Treatments

    The rivastigmine patch is the first transdermal treatment for Alzheimer disease (AD).

  8. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study

    ✓ Peer-reviewed alzhub usefulness score 72 out of 100. Sleep 2006-02-01 Brain scans and imaging

    Study objective Examine the effects of donepezil on sleep and rapid eye movement (REM) sleep electroencephalogram (EEG) in patients with Alzheimer disease, using polysomnography, and the correlation between REM sleep EEG parameters and cognitive scores.

All topic tags with their study counts